Assessment of the Prognostic Role of Neutrophil-to-lymphocyte Ratio Following Complete Resection of Thymoma

Overview

Journal J Cardiothorac Surg

Publisher Biomed Central

Specialties Cardiology & Vascular Diseases
General Surgery
Pulmonary Medicine

Date 2018 Nov 21

PMID 30454002

Citations 10

Authors

Piergiorgio Muriana

Angelo Carretta

Paola Ciriaco

Alessandro Bandiera

Giampiero Negri

Affiliations

Soon will be listed here.

Abstract

Background: The introduction of the new TNM staging system for thymic epithelial malignancies produced a significant increase in the proportion of patients with stage I disease. The identification of new prognostic factors could help to select patients for adjuvant therapies based on their risk of recurrence. Neutrophil-to-lymphocyte ratio (NLR) has recently gained popularity as reliable prognostic biomarker in many different solid tumors. The aim of this study is to assess the utility of NLR evaluation as a prognostic marker in patients with surgically-treated thymoma.

Methods: A retrospective analysis was conducted among patients who underwent resection for thymoma in a single center. Patients were divided in two groups, under (low-NLR-Group = 47 patients, 60%) and above (high-NLR-Group = 32 patients, 40%) a ROC-derived NLR cut-off (2.27). Associations with clinical-pathological variables were analyzed; disease-free survival (DFS) was identified as the primary endpoint.

Results: Between 2007 and 2017, 79 patients had surgery for thymoma. Overall 5-year DFS was 80%. Univariate survival analysis demonstrated that NLR was significantly related to DFS when patients were stratified for TNM stage (p = 0.043). Five-year DFS in the low-NLR-Group and in the high-NLR-Group were respectively 100 and 84% in stage I-II, and 66 and 0% in stage III. TNM stage resulted as the only independent prognostic factor at multivariate analysis, with hazard ratio of 3.986 (95% CI 1.644-9.665, p = 0.002).

Conclusions: High preoperative NLR seems to be associated to a shorter DFS in patients submitted to surgery for thymoma and stratified for TNM stage.

Citing Articles

Preoperative systemic immune-inflammation index for predicting the prognosis of thymoma with radical resection.

Li Q, Pu Y, Gong Z, Yu Y, Sun W, Cheng Z Thorac Cancer. 2023; 14(13):1192-1200.

PMID: 36951114 PMC: 10151138. DOI: 10.1111/1759-7714.14854.

Thymic Epithelial Tumors: An Evolving Field.

Kuhn E, Pescia C, Mendogni P, Nosotti M, Ferrero S Life (Basel). 2023; 13(2).

PMID: 36836670 PMC: 9964105. DOI: 10.3390/life13020314.

Prognostic factors and genetic markers in thymic epithelial tumors: A narrative review.

Agrafiotis A, Siozopoulou V, Hendriks J, Pauwels P, Koljenovic S, Van Schil P Thorac Cancer. 2022; 13(23):3242-3249.

PMID: 36349433 PMC: 9715802. DOI: 10.1111/1759-7714.14725.

Prognostic Value of Preoperative Nutritional Assessment and Neutrophil-to-Lymphocyte Ratio in Patients With Thymic Epithelial Tumors.

Huang Y, Liang S, Hu Y, Liu X, Ma G Front Nutr. 2022; 9:868336.

PMID: 35873441 PMC: 9305307. DOI: 10.3389/fnut.2022.868336.

Prognostic value of systemic inflammatory markers and the nutrition status in thymic epithelial tumors with complete resection.

Sakane T, Okuda K, Matsui T, Oda R, Tatematsu T, Yokota K Thorac Cancer. 2022; 13(15):2127-2133.

PMID: 35715991 PMC: 9346175. DOI: 10.1111/1759-7714.14485.

References

Ocana A, Nieto-Jimenez C, Pandiella A, Templeton A . Neutrophils in cancer: prognostic role and therapeutic strategies. Mol Cancer. 2017; 16(1):137. PMC: 5558711. DOI: 10.1186/s12943-017-0707-7. View

Detterbeck F, Stratton K, Giroux D, Asamura H, Crowley J, Falkson C . The IASLC/ITMIG Thymic Epithelial Tumors Staging Project: proposal for an evidence-based stage classification system for the forthcoming (8th) edition of the TNM classification of malignant tumors. J Thorac Oncol. 2014; 9(9 Suppl 2):S65-72. DOI: 10.1097/JTO.0000000000000290. View

Toker A, Sonett J, Zielinski M, Rea F, Tomulescu V, Detterbeck F . Standard terms, definitions, and policies for minimally invasive resection of thymoma. J Thorac Oncol. 2011; 6(7 Suppl 3):S1739-42. DOI: 10.1097/JTO.0b013e31821ea553. View

Zhao L, Zhou X, Li Z, Liu Y . Bone metastasis of malignant thymomas associated with peripheral T-cell lymphocytosis. BMC Surg. 2016; 16(1):58. PMC: 4992230. DOI: 10.1186/s12893-016-0171-0. View

Wu K, Mao J, Chen G, Fu X, Qian H, Jiang G . Prognostic predictors and long-term outcome of postoperative irradiation in thymoma: a study of 241 patients. Cancer Invest. 2009; 27(10):1008-15. DOI: 10.3109/07357900802563002. View

de Jong D, Richel D, Schenkeveld C, Boerrigter L, van t Veer L . Oligoclonal peripheral T-cell lymphocytosis as a result of aberrant T-cell development in a cortical thymoma. Diagn Mol Pathol. 1997; 6(4):244-8. DOI: 10.1097/00019606-199708000-00009. View

Buckley C, Douek D, Newsom-Davis J, Vincent A, Willcox N . Mature, long-lived CD4+ and CD8+ T cells are generated by the thymoma in myasthenia gravis. Ann Neurol. 2001; 50(1):64-72. DOI: 10.1002/ana.1017. View

Correa L, Correa R, Farinasso C, de SantAna Dourado L, Magalhaes K . Adipocytes and Macrophages Interplay in the Orchestration of Tumor Microenvironment: New Implications in Cancer Progression. Front Immunol. 2017; 8:1129. PMC: 5609576. DOI: 10.3389/fimmu.2017.01129. View

Hamaji M . The role of adjuvant chemotherapy following resection of early stage thymoma. Ann Cardiothorac Surg. 2016; 5(1):45-50. PMC: 4740096. DOI: 10.3978/j.issn.2225-319X.2015.09.03. View

10.

Pedraza M . Thymoma immunological and ultrastructural characterization. Cancer. 1977; 39(4):1455-61. DOI: 10.1002/1097-0142(197704)39:4<1455::aid-cncr2820390417>3.0.co;2-#. View

11.

Venuta F, Rendina E, Anile M, De Giacomo T, Vitolo D, Coloni G . Thymoma and thymic carcinoma. Gen Thorac Cardiovasc Surg. 2012; 60(1):1-12. DOI: 10.1007/s11748-011-0814-0. View

12.

Scorsetti M, Leo F, Trama A, DAngelillo R, Serpico D, Macerelli M . Thymoma and thymic carcinomas. Crit Rev Oncol Hematol. 2016; 99:332-50. DOI: 10.1016/j.critrevonc.2016.01.012. View

13.

Lombe D, Jeremic B . A Review of the Place and Role of Radiotherapy in Thymoma. Clin Lung Cancer. 2015; 16(6):406-12. DOI: 10.1016/j.cllc.2015.05.003. View

14.

Feng Y, Lei Y, Wu X, Huang Y, Rao H, Zhang Y . GTF2I mutation frequently occurs in more indolent thymic epithelial tumors and predicts better prognosis. Lung Cancer. 2017; 110:48-52. DOI: 10.1016/j.lungcan.2017.05.020. View

15.

Barton A . T-cell lymphocytosis associated with lymphocyte-rich thymoma. Cancer. 1997; 80(8):1409-17. DOI: 10.1002/(sici)1097-0142(19971015)80:8<1409::aid-cncr7>3.0.co;2-9. View

16.

Templeton A, McNamara M, Seruga B, Vera-Badillo F, Aneja P, Ocana A . Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis. J Natl Cancer Inst. 2014; 106(6):dju124. DOI: 10.1093/jnci/dju124. View

17.

Janik S, Bekos C, Hacker P, Raunegger T, Ghanim B, Einwallner E . Elevated CRP levels predict poor outcome and tumor recurrence in patients with thymic epithelial tumors: A pro- and retrospective analysis. Oncotarget. 2017; 8(29):47090-47102. PMC: 5564546. DOI: 10.18632/oncotarget.17478. View

18.

Smith G, Perkins S, Segal G, Kjeldsberg C . T-cell lymphocytosis associated with invasive thymomas. Am J Clin Pathol. 1994; 102(4):447-53. DOI: 10.1093/ajcp/102.4.447. View

19.

Carillo C, Diso D, Mantovani S, Pecoraro Y, De Giacomo T, Ciccone A . Multimodality treatment of stage II thymic tumours. J Thorac Dis. 2017; 9(8):2369-2374. PMC: 5594157. DOI: 10.21037/jtd.2017.06.116. View

20.

Koga K, Matsuno Y, Noguchi M, Mukai K, Asamura H, Goya T . A review of 79 thymomas: modification of staging system and reappraisal of conventional division into invasive and non-invasive thymoma. Pathol Int. 1994; 44(5):359-67. DOI: 10.1111/j.1440-1827.1994.tb02936.x. View